ELOX

SEC source: 0001415889-19-000111 · form4-01312019_040123.xml · derivative · entry 1

WEAVER GREGORY L · CIK 0001251779 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2029-01-30

F2 · price: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan.

F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on January 30, 2020, and the remainder vests in twelve equal quarterly installments thereafter.

SEC source: 0001415889-19-000110 · form4-01312019_040118.xml · derivative · entry 1

Ward Robert · CIK 0001595111 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 226,000

Underlying: Common Stock · 226,000 shares

Expires 2029-01-30

F2 · price: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan.

F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on January 30, 2020, and the remainder vests in twelve equal quarterly installments thereafter.

SEC source: 0001415889-18-001856 · form4-12282018_041201.xml · nonDerivative · entry 3

Ward Robert · CIK 0001595111 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,557

F3 · kind: Gift from the Robert E. Ward 2017 Revocable Trust to a family charitable foundation of which Mr. Ward is an officer, but he is not deemed to hold a pecuniary interest in the foundation.

F4 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F5 · balance_after: Reflects 80,557 shares held in the Robert E. Ward 2017 Revocable Trust.

SEC source: 0001415889-18-001856 · form4-12282018_041201.xml · derivative · entry 4

Ward Robert · CIK 0001595111 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 427,190

Underlying: Common Stock · 213,595 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock.

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F7 · price: The restricted stock units were issued pursuant to the Issuer's 2013 Share Ownership and Option Plan.

F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock.

F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock.

F8 · balance_after: The remaining restricted stock units will vest ratably each quarter over the next three years, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances.

SEC source: 0001415889-18-001856 · form4-12282018_041201.xml · nonDerivative · entry 2

Ward Robert · CIK 0001595111 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,557

SEC source: 0001415889-18-001856 · form4-12282018_041201.xml · nonDerivative · entry 1

Ward Robert · CIK 0001595111 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,595

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock.

F2 · balance_after: Of this amount, 130,557 shares have been transferred to the Robert E. Ward 2017 Revocable Trust of which Mr. Ward is a trustee.

SEC source: 0001209191-18-039558 · doc4.xml · derivative · entry 1

Williams Gregory C. · CIK 0001597293 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2028-06-25

F1 · derivative.exercise_date: One third (1/3) of the shares underlying the option shall vest on June 25, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each quarterly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

SEC source: 0001209191-18-039557 · doc4.xml · derivative · entry 1

Snow David P. · CIK 0001652972 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2028-06-25

F1 · derivative.exercise_date: One third (1/3) of the shares underlying the option shall vest on June 25, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each quarterly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

SEC source: 0001209191-18-038827 · doc4.xml · derivative · entry 1

Belloff Neil S. · CIK 0001741670 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2028-06-18

F1 · derivative.exercise_date: One third (1/3) of the shares underlying the option shall vest on June 18, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each quarterly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

SEC source: 0001209191-18-038664 · doc4.xml · derivative · entry 1

Veinrib Gadi · CIK 0001726015 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-06-15

F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

SEC source: 0001209191-18-038717 · doc4.xml · derivative · entry 1

Avnur Zafrira · CIK 0001726049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-06-15

F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

SEC source: 0001209191-18-038663 · doc4.xml · derivative · entry 1

Seehra Jasbir · CIK 0001732369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-06-15

F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

SEC source: 0001209191-18-038662 · doc4.xml · derivative · entry 1

Rubin Steven D · CIK 0001381874 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-06-15

F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

SEC source: 0001209191-18-038661 · doc4.xml · derivative · entry 2

Pontifax Management III G.P. (2011) Ltd. · CIK 0001726335 · 10% owner

Pontifax Management Fund III L.P. · CIK 0001726340 · 10% owner

Pontifax (Cayman) III, L.P. · CIK 0001726028 · 10% owner

Pontifax (Israel) III, L.P. · CIK 0001726038 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-06-15

F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

F3 · ownership.nature: The reported securities are owned directly by Ran Nussbaum, a general partner of Pontifax 3. Mr. Nussbaum will assign the economic interests of the reported securities to Pontifax 3 and it may be deemed the indirect beneficial owner of the security. Pontifax 3 disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein.

SEC source: 0001209191-18-038661 · doc4.xml · derivative · entry 1

Pontifax Management III G.P. (2011) Ltd. · CIK 0001726335 · 10% owner

Pontifax Management Fund III L.P. · CIK 0001726340 · 10% owner

Pontifax (Cayman) III, L.P. · CIK 0001726028 · 10% owner

Pontifax (Israel) III, L.P. · CIK 0001726038 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-06-15

F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

F2 · ownership.nature: The reported securities are owned directly by Tomer Kariv, a general partner of Pontifax Management III G.P. (2011) Ltd. ("Pontifax 3"). Mr. Kariv will assign the economic interests of the reported securities to Pontifax 3 and it may be deemed the indirect beneficial owner of the security. Pontifax 3 disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein.

SEC source: 0001209191-18-038659 · doc4.xml · derivative · entry 1

Nussbaum Ran · CIK 0001609805 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-06-15

F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

F2 · ownership.direct: The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a General Partner.

SEC source: 0001209191-18-038660 · doc4.xml · derivative · entry 2

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax IV GP L.P. · CIK 0001726353 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-06-15

F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

F3 · ownership.nature: The reported securities are owned directly by Ran Nussbaum, a general partner of Pontifax 4. Mr. Nussbaum will assign the economic interests of the reported securities to Pontifax 4 and it may be deemed the indirect beneficial owner of the security. Pontifax 4 disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein.

SEC source: 0001209191-18-038660 · doc4.xml · derivative · entry 1

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax IV GP L.P. · CIK 0001726353 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-06-15

F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

F2 · ownership.nature: The reported securities are owned directly by Tomer Kariv, a general partner of Pontifax Management 4 G.P. (2015) Ltd. ("Pontifax 4"). Mr. Kariv will assign the economic interests of the reported securities to Pontifax 4 and it may be deemed the indirect beneficial owner of the security. Pontifax 4 disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein.

SEC source: 0001209191-18-038658 · doc4.xml · derivative · entry 3

Noiman Silvia · CIK 0001340877 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-06-15

F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

SEC source: 0001209191-18-038658 · doc4.xml · derivative · entry 2

Noiman Silvia · CIK 0001340877 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,389

Underlying: Common Stock · 141,389 shares

Expires 2028-06-15

SEC source: 0001209191-18-038658 · doc4.xml · nonDerivative · entry 1

Noiman Silvia · CIK 0001340877 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,389

SEC source: 0001209191-18-038656 · doc4.xml · derivative · entry 1

Kleijwegt Martijn · CIK 0001726016 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-06-15

F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

SEC source: 0001209191-18-038654 · doc4.xml · derivative · entry 1

Kariv Tomer · CIK 0001568077 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-06-15

F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

F2 · ownership.direct: The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a General Partner.

SEC source: 0001209191-18-040022 · doc4.xml · derivative · entry 2

Noiman Silvia · CIK 0001340877 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 349,400 shares

Expires 2024-04-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The option was issued pursuant to the Company's Eloxx Pharmaceuticals Ltd. Share Ownership and Option Plan (2013) and was priced at Israeli New Shekel 0.0020. This amount reflects the U.S. dollar equivalent of the exercise price as of the transaction date using an exchange rate of 1:3.5736, as reported by Bloomberg.

F3 · derivative.exercise_date: The option was fully vested and exercisable as of October 26, 2016.

SEC source: 0001209191-18-040022 · doc4.xml · nonDerivative · entry 1

Noiman Silvia · CIK 0001340877 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 490,789

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The option was issued pursuant to the Company's Eloxx Pharmaceuticals Ltd. Share Ownership and Option Plan (2013) and was priced at Israeli New Shekel 0.0020. This amount reflects the U.S. dollar equivalent of the exercise price as of the transaction date using an exchange rate of 1:3.5736, as reported by Bloomberg.

F2 · balance_after: Represents the total number of shares owned by the Reporting Person as of the date of filing.

SEC source: 0001209191-18-032580 · doc4.xml · nonDerivative · entry 1

Ward Robert · CIK 0001595111 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

SEC source: 0001209191-18-031252 · doc4.xml · nonDerivative · entry 1

Huertas Pedro · CIK 0001389517 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,725

F1 · security: Represents a restricted stock unit ("RSU") award that will vest one quarter (1/4) of the RSUs on May 16, 2019 (the "Initial RSU Vesting Date") and one sixteenth (1/16) of the RSUs shall vest on each successive quarterly anniversary of the Initial RSU Vesting Date.

F1 · shares: Represents a restricted stock unit ("RSU") award that will vest one quarter (1/4) of the RSUs on May 16, 2019 (the "Initial RSU Vesting Date") and one sixteenth (1/16) of the RSUs shall vest on each successive quarterly anniversary of the Initial RSU Vesting Date.

SEC source: 0001209191-18-029518 · doc4.xml · nonDerivative · entry 1

Huertas Pedro · CIK 0001389517 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,725

F1 · security: Represents a restricted stock unit ("RSU") award that will vest one quarter (1/4) of the RSUs on March 12, 2019 (the "Initial RSU Vesting Date") and one sixteenth (1/16) of the RSUs shall vest on each successive quarterly anniversary of the Initial RSU Vesting Date.

F1 · shares: Represents a restricted stock unit ("RSU") award that will vest one quarter (1/4) of the RSUs on March 12, 2019 (the "Initial RSU Vesting Date") and one sixteenth (1/16) of the RSUs shall vest on each successive quarterly anniversary of the Initial RSU Vesting Date.

SEC source: 0001209191-18-029518 · doc4.xml · derivative · entry 2

Huertas Pedro · CIK 0001389517 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,725

Underlying: Common Stock · 104,725 shares

Expires 2028-05-10

F2 · derivative.exercise_date: This option will become exercisable with respect to one quarter (1/4) of the shares underlying the option shall vest on March 12, 2019 (the "Initial Option Vesting Date")and one sixteenth (1/16) of the shares underlying the option shall vest on each successive quarterly anniversary of the Initial Option Vesting Date.

SEC source: 0001209191-18-027116 · doc4.xml · nonDerivative · entry 1

Shabtai Gilad · CIK 0001726027 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,351,770

F1 · kind: Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018.

SEC source: 0001209191-18-027112 · doc4.xml · nonDerivative · entry 3

Nussbaum Ran · CIK 0001609805 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 520,396

F1 · kind: Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018.

F4 · ownership.nature: Represents shares of the Issuer held by Pontifax (China) IV, L.P. ("China IV"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-027112 · doc4.xml · nonDerivative · entry 2

Nussbaum Ran · CIK 0001609805 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 962,504

F1 · kind: Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018.

F3 · ownership.nature: Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-027112 · doc4.xml · nonDerivative · entry 1

Nussbaum Ran · CIK 0001609805 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 468,585

F1 · kind: Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018.

F2 · ownership.nature: Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. Mr. Nussbaum is a Managing Partner of Management 4. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-027114 · doc4.xml · nonDerivative · entry 3

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax IV GP L.P. · CIK 0001726353 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 520,396

F1 · kind: Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018.

F4 · ownership.nature: Represents shares of the Issuer held by Pontifax (China) IV L.P. ("China IV"). Pontifax IV GP L.P. is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-027114 · doc4.xml · nonDerivative · entry 2

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax IV GP L.P. · CIK 0001726353 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 962,504

F1 · kind: Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018.

F3 · ownership.nature: Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-027114 · doc4.xml · nonDerivative · entry 1

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax IV GP L.P. · CIK 0001726353 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 468,585

F1 · kind: Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018.

F2 · ownership.nature: Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-027108 · doc4.xml · nonDerivative · entry 1

Kleijwegt Martijn · CIK 0001726016 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By LSP investment fund

Disclosed balance after: 2,953,673

F1 · kind: Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018.

F2 · ownership.nature: Represents shares of the Issuer held by LSP V Cooperatieve U.A. ("LSP V"). LSP V Management B.V. ("LSP V Management") is the director and manager of LSP V. Mr. Kleijwegt is a Managing Director of LSP V Management. By virtue of this relationship, Mr. Kleijwegt may be deemed to share voting and dispositive power with respect to the shares held by LSP V. Mr. Kleijwegt disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-027105 · doc4.xml · nonDerivative · entry 3

Kariv Tomer · CIK 0001568077 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 520,396

F1 · kind: Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018.

F4 · ownership.nature: Represents shares of the Issuer held by Pontifax (China) IV, L.P. ("China IV"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-027105 · doc4.xml · nonDerivative · entry 2

Kariv Tomer · CIK 0001568077 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 962,504

F1 · kind: Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018.

F3 · ownership.nature: Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-027105 · doc4.xml · nonDerivative · entry 1

Kariv Tomer · CIK 0001568077 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 468,585

F1 · kind: Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018.

F2 · ownership.nature: Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. Mr. Kariv is a Managing Partner of Management 4. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-024125 · doc4.xml · nonDerivative · entry 2

Shabtai Gilad · CIK 0001726027 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,276,770

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.50 to $9.69666, inclusive.

SEC source: 0001209191-18-024125 · doc4.xml · nonDerivative · entry 1

Shabtai Gilad · CIK 0001726027 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,274,170

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.39 to $9.413, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.

SEC source: 0001209191-18-022544 · doc4.xml · nonDerivative · entry 1

Shabtai Gilad · CIK 0001726027 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,268,470

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.63 to $9.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

SEC source: 0001209191-18-021928 · doc4.xml · nonDerivative · entry 1

Avnur Zafrira · CIK 0001726049 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By: Spouse's IRA

Disclosed balance after: 2,263

SEC source: 0001209191-18-021645 · doc4.xml · nonDerivative · entry 1

Ward Robert · CIK 0001595111 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

SEC source: 0001209191-18-021643 · doc4.xml · nonDerivative · entry 1

WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,500

SEC source: 0001209191-18-021398 · doc4.xml · nonDerivative · entry 6

Nussbaum Ran · CIK 0001609805 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 427,063

F3 · ownership.nature: Represents shares of the Issuer held by Pontifax (China) IV, L.P. ("China IV"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-021398 · doc4.xml · nonDerivative · entry 5

Nussbaum Ran · CIK 0001609805 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 789,878

F2 · ownership.nature: Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-021398 · doc4.xml · nonDerivative · entry 4

Nussbaum Ran · CIK 0001609805 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 384,544

F1 · ownership.nature: Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. Mr. Nussbaum is a Managing Partner of Management 4. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-021395 · doc4.xml · nonDerivative · entry 6

Kariv Tomer · CIK 0001568077 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 427,063

F3 · ownership.nature: Represents shares of the Issuer held by Pontifax (China) IV, L.P. ("China IV"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.